TABLE 1.
Activities of CSA-13, CSA-8, and comparator antimicrobial agents of 4 clinical strains of VRSA and 50 clinical isolates of hGISA and GISA
| Antimicrobial agent | MIC (μg/ml)/MBC (μg/ml) for hGISA/GISAa strains (n = 50)
|
MIC (μg/ml)/MBC (μg/ml)
|
|||||
|---|---|---|---|---|---|---|---|
| Range | 50% | 90% | VRSA-NY (2004) | VRSA-MI (2002) | VRSA-PA (2002) | VRSA-MI (2005) | |
| CSA-8 | 4-8/4-16 | 4/8 | 8/8 | 4/4 | 4/4 | 4/4 | 4/4 |
| CSA-13 | 1-2/1-2 | 1/1 | 1/1 | 1/1 | 1/1 | 1/1 | 1/1 |
| Daptomycin | 0.125-1/0.125-1 | 0.5/0.5 | 1/1 | 0.125/0.125 | 0.125/0.125 | 0.5/1 | 0.125/0.125 |
| Linezolid | 0.25-2/0.5-64 | 1/8 | 2/64 | 1/16 | 2/4 | 2/8 | 0.25/0.5 |
| Vancomycin | 1-8/1-16 | 4/8 | 8/8 | 1024/>2,048 | 32/64 | 256/>256 | 128/>256 |
a
hGISA/GISA, glycopeptide-intermediate S. aureus; heterogeneous glycopeptide-intermediate S. aureus.